Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Promising novel antibody therapies for AML

Farhad Ravandi • 11 Mar 2021
EBMT 2021
Acute Myeloid Leukemia Leukemia AMG 330 AMG 472 AMG 673 Antibodies Flotetuzumab Gemtuzumab ozogamicin XmAb14045

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares an update on the most promising novel antibody therapies for the treatment of acute myeloid leukemia (AML). Dr Ravandi discusses CD33- targeting antibodies, in particular gemtuzumab ozogamicin, and other promising targets, such as CD123. Dr Ravandi also outlines the potential benefits of bispecific T-cell engagers such as flotetuzumab, AMG 330, AMG 673, AMG 472 and XmAb14045. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

More from Farhad Ravandi

1:23
The value of MRD as a marker for disease eradication in AML
Farhad Ravandi • 8 Dec 2023
1:31
Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi • 8 Dec 2023
1:29
Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Farhad Ravandi • 8 Dec 2023
1:43
Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL
Farhad Ravandi • 8 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals